



MINUTES

Utah Department of Health
Drug Utilization Review Board

Thursday, March 12, 2015
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 125

Board Members Present:

Tony Dalpiaz, PharmD.
Michael Symond, M.D.
Keith Tolman, M.D.
Jay Aldus, DDS

Jennifer Brinton, MD
George Hamblin, PharmD
Susan Siegfried, M.D

Board Members Excused:

Kyle Jones, M.D.
Mr. Kumar Shah

Mark Balk, PharmD.

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, Pharm.D
Trevor Smith C.Ph.T.
Heather Santacruz, R.N .

Lisa Hunt, RPh
Merelynn Berrett, R.N.
Alyssa Pitts, R.N.

Other Individuals Present:

Gary Oderda, UofU
Elizabeth Ariano, Indivior
Clayne Garrett, Biogen Idec
Sumar Bieda, Purdue
Cody Ball, Select Health

Paul Bragoli, Indivior
DR McCale, Baxter
Joanita Lake, UofU
David Wickard, Baxter
Lee Marks, Orexo

Meeting conducted by: Tony Dalpiaz, Pharm.D.

- 1. Welcome** – Tony Dalpiaz opened the meeting.
- 2. Housekeeping** – Robyn Seely welcomed everyone to the meeting and reminded everyone to sign in. She said that there is one petition for the board that will be reviewed following the public meeting today. She also welcomed the new Prior Authorization nurse, Alyssa Pitts who recently joined Utah Medicaid.
- 3. P&T Committee report** – Lisa Hunt said that the next P&T committee meeting will discuss diuretic agents. She passed out the tentative schedule for the rest of the year.
- 4. Approval of prior meeting minutes** – Pending the correction of one typo, Keith Tolman made a motion to approve the February meeting minutes. Jennifer Brinton seconded the motion. All in favor.

5. **Nine month review** – Robyn Seely said that nine months ago, the DUR board first began discussing Hepatitis C, but the topic was discussed again at subsequent meetings, so she will delay reviewing it for now.

6. **Annual Public Meeting Training – Tony Patterson, State AG Office**

- a. He said that there is a requirement to provide any information presented via electronic means such as a slide show to the public.
 - b. He said that board members can't transmit electronic information through text messages or chats or emails to each other during the meeting
 - c. He explained that social gatherings or chance meetings won't be considered a public meeting. He then said that decisions or motions can't be made in those settings.
 - d. He offered to answer any questions from the board
7. **Buprenorphine single entity products** – Joanita Lake from the University of Utah DRRC presented drug information including disease symptoms, studies, side effects, indications and other information about the buprenorphine single agent drugs in this class. Data was also presented about the utilization of the drugs in the Utah Medicaid population in previous years.

8. **Public Comment**

- a. No Public Comment.

9. **Board Discussion on MS oral agents**

- a. Robyn Seely presented the current PA criteria sheet for the single agent buprenorphine.
- b. Keith Tolman asked about X-DEA numbers and Utah Medicaid policy on the use of them. Robyn responded saying that it is a part of the PA requirement to have the prescriber have a valid X-DEA number.
- c. Mike Symond questioned why the PA allows for 36 months for use during pregnancy, since pregnancy won't go beyond 9 months.
- d. Susan Siegfried asked about HIV/AIDS patients and patients with hepatic insufficiency where the combination products with naloxone do not work.
- e. Robyn Seely responded to Susan that since those indications are not included with the FDA approved indications, they are not included on the PA sheet.
- f. George Hamblin discussed making a motion to have an initial PA for nine or ten months to account for the usage during pregnancy.
- g. Jennifer Brinton asked about nursing mothers who may still require the single agent.
- h. Joanita Lake said that the information says that caution should be used when given to nursing mothers.
- i. A question was asked about the percentage of patients are using the single agent product for pregnancy versus an allergy or side effect to the combination agent.
- j. Keith Tolman said that he recommends that we don't restrict this drug dramatically from what it currently is listed as the criteria, as the patient is already

on a management program.

- k. Jennifer Brinton made a motion to accept the draft PA criteria on the single agent buprenorphine products. George Hamblin seconded the motion. All in favor.
- l. Susan Siegfried made a request to include more information about diagnosis codes for the next review. Robyn said that if the board desires, they can move to include a mandate to require a diagnosis code.
- m. Mike Symond said that it is a burden on the providers to have a mandate to include the diagnosis code on the prescription. Others were in agreement.
- n. George Hamblin made a motion to adjourn the meeting. Mike Symond seconded the motion. All in favor.

10. Meeting Adjourned

The next DUR Board meeting is scheduled for Thursday, April 9th. Botulinum Toxins: Pharmacy and Medical PA requirements and Afrezza will be discussed.

Minutes prepared by Trevor Smith.

Recording available upon request, send email to medicaidpharmacy@utah.gov